Faculty

Back to Index
Annie Yessaian, MD
Assistant Professor of Clinical Obstetrics & Gynecology
Associate Director Gynecology Oncology Fellowship
Director of The Gynecology/Oncology Outreach Program
Obstetrics & Gynecology
IRD 520 2020 Zonal Ave Off Campus Los Angeles
+1 323 226 3183

Overview

Dr. Yessaian graduated from the University of Baghdad Medical School, Iraq in 1989 with high honors and ranking the first of her class in surgery and obstetrics & gynecology. She then further trained in a rotating internship for two years in Baghdad. Dr. Yessaian then joined the residency training program in general surgery at Maimonides Medical Center-Brooklyn NY, where she also received four additional years of obstetrics & gynecology training. She completed her residency in 1998, receiving the award of “Best Chief Resident of the Year." Dr. Yessaian received further training in a research fellowship in molecular biology at Memorial Sloan Kettering Cancer Center, studying platinum resistance in ovarian cancer. She also joined the gynecologic oncology fellowship program at UC Irvine for four more years, where her research areas included angiogenesis in ovarian cancer. Dr. Yessaian received the Society of Gynecologic Oncologist award for best paper presented by a fellow in 2002. In 2004, Dr. Yessaian joined USC as an Assistant professor of clinical Ob-gyn, Gynecologic Oncology and her current areas of research include cervical cancer, sarcomas and thrombosis in women with gynecologic malignancies.

Publications

Patient compliance for postoperative radiotherapy and survival outcome of women with stage I endometrioid endometrial cancer. J Surg Oncol. 2017 Sep; 116(4):482-491. View in: PubMed

Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. Gynecol Oncol. 2016 Dec; 143(3):650-654. View in: PubMed

Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. Gynecol Oncol. 2016 Oct 19. View in: PubMed

Microfocus of Anaplastic Carcinoma Arising in Mural Nodule of Ovarian Mucinous Borderline Tumor With Very Rapid and Fatal Outcome. Int J Gynecol Pathol. 2016 Jul; 35(4):348-51. View in: PubMed

Predictive Factor of Conversion to Laparotomy in Minimally Invasive Surgical Staging for Endometrial Cancer. Int J Gynecol Cancer. 2016 Feb; 26(2):290-300. View in: PubMed

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol. 2015 Dec; 161(2):197-208. View in: PubMed

Predictive Factor of Conversion to Laparotomy in Minimally Invasive Surgical Staging for Endometrial Cancer. Int J Gynecol Cancer. 2015 Nov 14. View in: PubMed

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized poly-I:C. Clin Immunol. 2015 Sep 7. View in: PubMed

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy. Cancer Microenviron. 2014 Aug; 7(1-2):33-9. View in: PubMed

Predictive model of venous thromboembolism in endometrial cancer. Gynecol Oncol. 2013 Mar; 128(3):544-51. View in: PubMed

Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 2012 Dec; 5(6):469-74. View in: PubMed

Significance of perioperative infection in survival of patients with ovarian cancer. Int J Gynecol Cancer. 2012 Feb; 22(2):245-53. View in: PubMed

Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer. Oncologist. 2012; 17(12):1598-9. View in: PubMed

Population characteristics in cervical cancer trials: search for external validity. Am J Obstet Gynecol. 2005 Feb; 192(2):407-13. View in: PubMed

Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol. 2004 Jul; 94(1):61-6. View in: PubMed

Powered bySC CTSI